Key facts
- MedWatch Technologies’s last known valuation is $62.5M (Mar 2026).
- It has raised $17.6M; the latest was Early Stage VC ($17.6M) in Mar 2026.
- Notable investors include Front Porch Venture Partners, Solyco Capital, Stead Impact Ventures and Foundation.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for MedWatch Technologies
- ·The full record, as it builds
Funding rounds
No funding rounds for MedWatch Technologies are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About MedWatch Technologies
Developer of a non-invasive health management platform designed for people suffering from diabetes. The company's platform monitors glucose levels and provides customers with new tools to continuously adjust their diet and lifestyle in response to their immediate glucose condition, combines biosensing and AI coaching to deliver a comprehensive proactive health management experience, enabling patients to monitor blood glucose levels affordably, and with less discomfort.
- Sector
- Healthcare
- HQ
- Las Vegas, NV, United States
- Founded
- 2022
- Website
- medwatchtech.com/
- Ownership
- Privately Held (backing)
MedWatch Technologies doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in MedWatch Technologies shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on MedWatch Technologies in its N-PORT filings yet. We sweep new filings monthly.